Search

Travel grants

Travel grant submission is now closed

Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and reside in one of the upper-middle, lower-middle, and low-income countries.

Read more

Faculty information

We are honored that you have agreed to be part of the faculty for the Highlights of Past EHA (HOPE) MENA 2023, to be held on November 4, 2023 in Antalya, Türkiye.

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

Travel Grants

Application for a travel grant closed on August 29

Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and are reserved for applicants from upper-middle, lower-middle, and low-income countries.

Read more

EHA Research Conference

On this page, you will find the Sponsor Program for the EHA Research Conference 2024.  If the Sponsor Program does not display correctly, please click here or download the file. Click here to learn more about the meeting.

Read more

EHA-SfPM Precision Medicine Meeting

On this page, you will find the Sponsor Program for the EHA-SfPM Precision Medicine Meeting.  If the Sponsor Program does not display correctly, please click here or download the file.

Read more

EHA response to the EU’s Pharma Revision

Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.

Read more

Meeting Program

For the program please click here.  

If you would like a printable / PDF version of the program, you can download it via the 'Scientific Programme' tab in the above linked planner.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more